Clinical Trial

ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2, Open-label, Single-arm, Window of opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients with Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-12-20; most recent amendment 2024-08-14.
Status change: Recruiting → Active, Not Recruiting 2024-08-14
Status change: Not Yet Recruiting → Recruiting 2022-02-04
Trial Details
NCT Number NCT05182866
Lead Sponsor Rakuten Medical, Inc.
Collaborators: Shimadzu Corporation, National Cancer Institute (NCI)
Conditions Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Enrollment 9 participants
Start Date 2022-01-21
Primary Completion 2024-07-11 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-08-16